Tigenix to Get 4.95 Million-Euro Loan for Crohn’s Fistula Study

TiGenix NV (TIG)’s Cellerix unit will get a 4.95 million-euro loan from the “Madrid Network” to finance the company’s phase III study for complex perianal fistulas in Crohn’s disease patients, TiGenix said today in an e-mailed statement.

To contact the editor responsible for this story: Andrew Clapham at aclapham@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.